Novavax Inc on Tuesday delayed the timeline for beginning a late-stage U.S. trial of its experimental coronavirus vaccine by roughly one month.
The company said it would begin the trial by the end of November. It previously expected to start this month.
Novavax said it also expects interim data from an ongoing late-stage UK trial of its coronavirus vaccine in the first quarter of next year.
The company said it had expanded its enrollment target in the UK trial to 15,000 volunteers from 10,000. It expects this could help assess safety and effectiveness of the vaccine in a shorter time period.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News and Breaking News here
Comments
0 comment